Mallia Innovations Secures European Patent for sCD83

Mallia Innovations has received a European patent for the use of soluble CD83 (sCD83) protein in hair growth and wound healing. This new patent covers both therapeutic and cosmetic applications, indicating the potential of sCD83 to stimulate hair follicle stem cells and reduce local inflammation.

The patent, numbered 4,135,745, allows for local and systemic applications, potentially addressing conditions like androgenetic alopecia and chronic wounds. sCD83’s multimodal action mechanisms are pivotal, promoting an anti-inflammatory environment, halting cell death in hair follicles, and directly encouraging hair growth.

Prof. Dr. Alexander Steinkasserer, co-founder, highlights the significance of this patent in advancing novel treatments for hair loss and wound healing. The patent solidifies Mallia’s efforts in developing effective therapeutics and cosmetic products, leveraging sCD83’s unique characteristics.